Amit Lakhanpal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amit Lakhanpal has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Susan M. Goodman
Hospital for Special Surgery New York City New York
3 shared publications - Dana E. Orange
Hospital for Special Surgery, New York, NY, USA
2 shared publications - Daniel C. Ramirez
Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, NY 10021, USA
2 shared publications - Edward F. DiCarlo
Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, NY 10021, USA
2 shared publications - Ernest Brahn
Division of Rheumatology, UCLA School of Medicine, Los Angeles, CA, USA
2 shared publications - Laura T. Donlin
Immunology and Microbial Pathogenesis Graduate Program, Weill Cornell Graduate School, New York, NY 10065, USA
2 shared publications
Latest Publications
- Top Cited Papers
- 24 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (855) , eaed3087
SPP1 hi macrophages in fibrin niches promote hyperplastic tissue remodeling in rheumatoid arthritis synovium
In chronic inflammatory diseases, maladaptive tissue remodeling is driven by a complex interplay of resident cells, immune infiltrates, and the extracellular matrix. In the autoimmune disorder rheumatoid arthritis (RA), synovial tissue undergoes massive expansion to form an invasive pannus that drives the erosion of cartilage and bone. The mechanisms mediating this aggressive growth are incompletely defined. Using spatial transcriptomic profiling of patient tissue, we detected an abundance of proliferating fibroblasts near the synovial tissue lining surface and adjacent to macrophages expressing high levels of secreted phosophoprotein-1 (encoding osteopontin; SPP1 hi macrophages). These synovial lining regions were also distinctly marked by deposits of the clot-forming protein fibrin. Although the SPP1 hi macrophages phenotypically resembled the profibrotic macrophages that drive lung and liver fibrosis, these niches were devoid of the dense highly ordered collagen that marks fibrosis. Functionally, we found that SPP1 hi macrophages degraded and phagocytosed fibrin matrices and promoted fibroblast proliferation. Given that fibrin provides transient matrices for de novo tissue generation in the context of wound healing, these data support a model of hyperplastic tissue outgrowth involving SPP1 hi macrophages, fibroblasts, and fibrin matrices adhered to the exterior synovial tissue surface. Whereas current RA therapies primarily aim to dampen proinflammatory responses, our findings provide the rationale for targeting progenerative pathways and SPP1 hi macrophages.
- 24 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (855) , eaed3087
Top Cited PapersSPP1 hi macrophages in fibrin niches promote hyperplastic tissue remodeling in rheumatoid arthritis synovium
In chronic inflammatory diseases, maladaptive tissue remodeling is driven by a complex interplay of resident cells, immune infiltrates, and the extracellular matrix. In the autoimmune disorder rheumatoid arthritis (RA), synovial tissue undergoes massive expansion to form an invasive pannus that drives the erosion of cartilage and bone. The mechanisms mediating this aggressive growth are incompletely defined. Using spatial transcriptomic profiling of patient tissue, we detected an abundance of proliferating fibroblasts near the synovial tissue lining surface and adjacent to macrophages expressing high levels of secreted phosophoprotein-1 (encoding osteopontin; SPP1 hi macrophages). These synovial lining regions were also distinctly marked by deposits of the clot-forming protein fibrin. Although the SPP1 hi macrophages phenotypically resembled the profibrotic macrophages that drive lung and liver fibrosis, these niches were devoid of the dense highly ordered collagen that marks fibrosis. Functionally, we found that SPP1 hi macrophages degraded and phagocytosed fibrin matrices and promoted fibroblast proliferation. Given that fibrin provides transient matrices for de novo tissue generation in the context of wound healing, these data support a model of hyperplastic tissue outgrowth involving SPP1 hi macrophages, fibroblasts, and fibrin matrices adhered to the exterior synovial tissue surface. Whereas current RA therapies primarily aim to dampen proinflammatory responses, our findings provide the rationale for targeting progenerative pathways and SPP1 hi macrophages.
- 15 June 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (10) , 1090-1097
Clinical and Histopathologic Characteristics and Outcomes of Patients With Psoriatic Arthritis Undergoing Arthroplasty
Objective: Patients with psoriatic arthritis (PsA) experience higher postoperative complication rates after total hip or total knee arthroplasty (THA and TKA, respectively) than patients with osteoarthritis, but contributing factors to this risk are poorly defined. We examined clinical factors predicting postoperative complications to determine whether PsA-specific disease activity is associated with adverse events (AEs). Methods: We conducted a prospective study of adults with PsA undergoing THA or TKA. Baseline assessments included demographics, BMI, Charlson Comorbidity Index (CCI), PsA disease activity measures, patient global assessment, medications, and patient-reported outcomes. Operative synovial tissue was assessed for inflammation. Postoperative AEs collected within 1 year were graded for severity (1-4) using the Clavien-Dindo (CD) classification. Logistic regression, adjusting for age and sex, assessed predictors of AEs and AE severity. Results: In total, 57 patients were included (24 THA, 33 TKA). At surgery, patients had moderate PsA activity (mean Disease Activity Index for Psoriatic Arthritis [DAPSA] score of 15.8) with minimal skin disease or enthesitis. CD grade 3-4 AEs occurred in 10 patients (18%). BMI and CCI were higher in THA patients with any AEs and all patients with grade 3-4 AEs. In the adjusted analysis, higher CCI was associated with grade 2-4 and 3-4 AEs, and BMI with grade 3-4 AEs. No PsA-specific measures, including DAPSA or synovial histologic inflammation, were associated with AEs. Conclusion: In patients with PsA undergoing THA/TKA, AEs were driven by comorbidity burden and obesity rather than PsA-specific disease activity or joint inflammation. This finding highlights the importance of perioperative optimization of comorbidities and weight.
- 15 June 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (10) , 1090-1097
Clinical and Histopathologic Characteristics and Outcomes of Patients With Psoriatic Arthritis Undergoing Arthroplasty
Objective: Patients with psoriatic arthritis (PsA) experience higher postoperative complication rates after total hip or total knee arthroplasty (THA and TKA, respectively) than patients with osteoarthritis, but contributing factors to this risk are poorly defined. We examined clinical factors predicting postoperative complications to determine whether PsA-specific disease activity is associated with adverse events (AEs). Methods: We conducted a prospective study of adults with PsA undergoing THA or TKA. Baseline assessments included demographics, BMI, Charlson Comorbidity Index (CCI), PsA disease activity measures, patient global assessment, medications, and patient-reported outcomes. Operative synovial tissue was assessed for inflammation. Postoperative AEs collected within 1 year were graded for severity (1-4) using the Clavien-Dindo (CD) classification. Logistic regression, adjusting for age and sex, assessed predictors of AEs and AE severity. Results: In total, 57 patients were included (24 THA, 33 TKA). At surgery, patients had moderate PsA activity (mean Disease Activity Index for Psoriatic Arthritis [DAPSA] score of 15.8) with minimal skin disease or enthesitis. CD grade 3-4 AEs occurred in 10 patients (18%). BMI and CCI were higher in THA patients with any AEs and all patients with grade 3-4 AEs. In the adjusted analysis, higher CCI was associated with grade 2-4 and 3-4 AEs, and BMI with grade 3-4 AEs. No PsA-specific measures, including DAPSA or synovial histologic inflammation, were associated with AEs. Conclusion: In patients with PsA undergoing THA/TKA, AEs were driven by comorbidity burden and obesity rather than PsA-specific disease activity or joint inflammation. This finding highlights the importance of perioperative optimization of comorbidities and weight.
- Open Access
- 2 February 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (2) , e70156
Synovial Fluid Cell Counts and the Degree of Synovial Tissue Lymphocytic Inflammation in Patients with Rheumatoid Arthritis
Objective: The synovial tissue pathotype may determine the treatment response in rheumatoid arthritis (RA); however, biopsies are not widely available. Synovial fluid is a promising tissue surrogate. Our purpose was to compare RA synovial fluid cell counts with histopathology and use synovial fluid to predict tissue inflammation. Methods: Synovial fluid and tissue were collected during knee arthroplasty. Patients were stratified based on their medication treatment history. Synovial lymphocytic inflammation (SLI) was graded from low to high. Synovial fluid white blood cell (WBC) count and differentials were performed in the clinical laboratory. Descriptive statistics, correlations, receiver operating characteristic curve analysis, and multivariable regression were performed to determine the associations with tissue SLI. Results: Sixty‐four patients with RA had paired synovial tissue and synovial fluid data available. The mean Clinical Disease Activity Index (CDAI) score was 17.9. High tissue SLI was observed in 29 patients, and low SLI was observed in 35 patients, with roughly equal distribution among treatment groups. The mean synovial fluid WBC count was 5,661 cells/μL and was not correlated with CDAI but correlated positively with SLI and percentage polymorphonuclear cells (PMN%). Synovial fluid WBC count ≥1,400 cells/μL was sensitive (0.86) and specific (0.91) for high SLI (area under the curve 0.91). In a multivariable regression, PMN% was associated with high SLI (odds ratio [OR] 1.46 [95% confidence interval (CI) 1.14–1.85]). Synovial fluid monocyte percentage was negatively associated with high SLI (OR 0.44 [95% CI 0.27–0.73]). Conclusion: Synovial fluid WBC count is sensitive and specific for differentiating high and low lymphocytic synovial inflammation. Further analysis of the synovial fluid as it relates to the adjacent tissue in different cohorts is needed. image
- 2 February 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (2) , e70156
Open AccessSynovial Fluid Cell Counts and the Degree of Synovial Tissue Lymphocytic Inflammation in Patients with Rheumatoid Arthritis
Objective: The synovial tissue pathotype may determine the treatment response in rheumatoid arthritis (RA); however, biopsies are not widely available. Synovial fluid is a promising tissue surrogate. Our purpose was to compare RA synovial fluid cell counts with histopathology and use synovial fluid to predict tissue inflammation. Methods: Synovial fluid and tissue were collected during knee arthroplasty. Patients were stratified based on their medication treatment history. Synovial lymphocytic inflammation (SLI) was graded from low to high. Synovial fluid white blood cell (WBC) count and differentials were performed in the clinical laboratory. Descriptive statistics, correlations, receiver operating characteristic curve analysis, and multivariable regression were performed to determine the associations with tissue SLI. Results: Sixty‐four patients with RA had paired synovial tissue and synovial fluid data available. The mean Clinical Disease Activity Index (CDAI) score was 17.9. High tissue SLI was observed in 29 patients, and low SLI was observed in 35 patients, with roughly equal distribution among treatment groups. The mean synovial fluid WBC count was 5,661 cells/μL and was not correlated with CDAI but correlated positively with SLI and percentage polymorphonuclear cells (PMN%). Synovial fluid WBC count ≥1,400 cells/μL was sensitive (0.86) and specific (0.91) for high SLI (area under the curve 0.91). In a multivariable regression, PMN% was associated with high SLI (odds ratio [OR] 1.46 [95% confidence interval (CI) 1.14–1.85]). Synovial fluid monocyte percentage was negatively associated with high SLI (OR 0.44 [95% CI 0.27–0.73]). Conclusion: Synovial fluid WBC count is sensitive and specific for differentiating high and low lymphocytic synovial inflammation. Further analysis of the synovial fluid as it relates to the adjacent tissue in different cohorts is needed. image
- Open Access
- 14 May 2020
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 7 (2) , S102-S106
A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics
Cite this article as: Lakhanpal A, Brahn E. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics. Eur J Rheumatol 2020; 7(Suppl 2): S102-6.
- 14 May 2020
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 7 (2) , S102-S106
Open AccessA perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics
Cite this article as: Lakhanpal A, Brahn E. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics. Eur J Rheumatol 2020; 7(Suppl 2): S102-6.
- 6 October 2016
- Published by Springer Nature in Clinical Rheumatology
- Vol. 35 (12) , 2869-2875
Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions
Biologics as therapeutic interventions for human disease represent both a distinctly modern novelty and an echo of ancient, or at least old, medical practice. The similarity lies in the sense that in both the synthetic effort occurs in living organisms (an extract of a plant, animal tissue, or a cell culture) while the difference is apparent in the bioengineering required in modern methods and the corresponding flexibility to customize the therapeutic product. Although the concept of looking to living systems as a source of medically useful compounds either for research or for actual patient care has never vanished, the development of biochemistry and advances in medicinal chemistry made production by total synthesis the standard for a safe, reliable, and commercial drug production at sufficient scale. In this interval was where much of the modern apparatus for approving medical therapies came to be developed, and as such, the most proper extension of the regulatory regime to modern biologics is not entirely obvious. In particular, the notion of generics for off-patent conventional pharmaceuticals and their role in the marketplace with respect to increasing the accessibility of treatment is not congruent with the relationship between what are known as biosimilars and off-patent originating biologics. In this article, we review elements of the scientific basis for challenges in the production, use, and regulation of biosimilars. In light of these advances, we propose suggestions to modify constraints on biosimilar regulations in the interest of patient care and access to therapies.
- 6 October 2016
- Published by Springer Nature in Clinical Rheumatology
- Vol. 35 (12) , 2869-2875
Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions
Biologics as therapeutic interventions for human disease represent both a distinctly modern novelty and an echo of ancient, or at least old, medical practice. The similarity lies in the sense that in both the synthetic effort occurs in living organisms (an extract of a plant, animal tissue, or a cell culture) while the difference is apparent in the bioengineering required in modern methods and the corresponding flexibility to customize the therapeutic product. Although the concept of looking to living systems as a source of medically useful compounds either for research or for actual patient care has never vanished, the development of biochemistry and advances in medicinal chemistry made production by total synthesis the standard for a safe, reliable, and commercial drug production at sufficient scale. In this interval was where much of the modern apparatus for approving medical therapies came to be developed, and as such, the most proper extension of the regulatory regime to modern biologics is not entirely obvious. In particular, the notion of generics for off-patent conventional pharmaceuticals and their role in the marketplace with respect to increasing the accessibility of treatment is not congruent with the relationship between what are known as biosimilars and off-patent originating biologics. In this article, we review elements of the scientific basis for challenges in the production, use, and regulation of biosimilars. In light of these advances, we propose suggestions to modify constraints on biosimilar regulations in the interest of patient care and access to therapies.